<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is a progressive disease associated with high levels of morbidity and mortality and for which there is both a large and growing prevalence worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>Lifestyle advice plus <z:chebi fb="0" ids="6801">metformin</z:chebi> is commonly recommended initially to manage <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> and to minimize the risk of vascular complications </plain></SENT>
<SENT sid="2" pm="."><plain>However, additional agents are required when glycemic targets cannot be achieved or maintained due to the progressive nature of the disease </plain></SENT>
<SENT sid="3" pm="."><plain>Repaglinide/<z:chebi fb="0" ids="6801">metformin</z:chebi> fixed-dose combination (<z:chebi fb="17" ids="38848">FDC</z:chebi>) therapy (PrandiMet(®); Novo Nordisk, Bagsværd, Denmark) has been approved for use in the USA </plain></SENT>
<SENT sid="4" pm="."><plain>This <z:chebi fb="17" ids="38848">FDC</z:chebi> is a rational second-line therapy given the complementary mechanisms of action of the components </plain></SENT>
<SENT sid="5" pm="."><plain>Repaglinide is a rapidly absorbed, short-acting insulin secretagogue targeting postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> excursions; <z:chebi fb="0" ids="6801">metformin</z:chebi> is an insulin sensitizer with a longer duration of action that principally regulates basal <z:chebi fb="105" ids="17234">glucose</z:chebi> levels </plain></SENT>
<SENT sid="6" pm="."><plain>A pivotal, 26-week, randomized study with repaglinide/<z:chebi fb="0" ids="6801">metformin</z:chebi> <z:chebi fb="17" ids="38848">FDC</z:chebi> therapy has been conducted in patients experiencing suboptimal control with previous oral antidiabetes therapy </plain></SENT>
<SENT sid="7" pm="."><plain>Repaglinide/<z:chebi fb="0" ids="6801">metformin</z:chebi> <z:chebi fb="17" ids="38848">FDC</z:chebi> improved glycemic control and weight neutrality without adverse effects on <z:chebi fb="23" ids="18059">lipid</z:chebi> profiles </plain></SENT>
<SENT sid="8" pm="."><plain>There were no major <z:hpo ids='HP_0001988'>hypoglycemic episodes</z:hpo> and patients expressed greater satisfaction with repaglinide/<z:chebi fb="0" ids="6801">metformin</z:chebi> <z:chebi fb="17" ids="38848">FDC</z:chebi> than previous treatments </plain></SENT>
<SENT sid="9" pm="."><plain>Repaglinide/<z:chebi fb="0" ids="6801">metformin</z:chebi> <z:chebi fb="17" ids="38848">FDC</z:chebi> is expected to be more convenient than individual tablets for patients taking repaglinide and <z:chebi fb="0" ids="6801">metformin</z:chebi> in loose combination, and it is expected to improve glycemic control in patients for whom meglitinide or <z:chebi fb="0" ids="6801">metformin</z:chebi> monotherapies provide inadequate control </plain></SENT>
</text></document>